Zosano Pharma Corporation (ZSAN): Price and Financial Metrics


Zosano Pharma Corporation (ZSAN): $1.90

0.17 (+9.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZSAN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ZSAN POWR Grades


  • Growth is the dimension where ZSAN ranks best; there it ranks ahead of 82.49% of US stocks.
  • The strongest trend for ZSAN is in Quality, which has been heading up over the past 113 days.
  • ZSAN ranks lowest in Quality; there it ranks in the 1st percentile.

ZSAN Stock Summary

  • With a market capitalization of $35,662,809, Zosano Pharma Corp has a greater market value than only 6.61% of US stocks.
  • With a price/sales ratio of 45.43, Zosano Pharma Corp has a higher such ratio than 95.86% of stocks in our set.
  • Revenue growth over the past 12 months for Zosano Pharma Corp comes in at 250.45%, a number that bests 96.65% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ZSAN, based on their financial statements, market capitalization, and price volatility, are INFI, ATNM, LCTX, SONN, and BBI.
  • ZSAN's SEC filings can be seen here. And to visit Zosano Pharma Corp's official web site, go to www.zosanopharma.com.

ZSAN Valuation Summary

  • In comparison to the median Healthcare stock, ZSAN's price/earnings ratio is 107.12% lower, now standing at -2.6.
  • Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.
  • Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.

Below are key valuation metrics over time for ZSAN.

Stock Date P/S P/B P/E EV/EBIT
ZSAN 2021-08-31 121.9 1.9 -2.6 -2.3
ZSAN 2021-08-30 116.4 1.8 -2.5 -2.2
ZSAN 2021-08-27 120.6 1.9 -2.6 -2.3
ZSAN 2021-08-26 120.4 1.9 -2.6 -2.3
ZSAN 2021-08-25 118.1 1.8 -2.5 -2.3
ZSAN 2021-08-24 116.1 1.8 -2.5 -2.2

ZSAN Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -32.23%.
  • Its 2 year cash and equivalents growth rate is now at 432.25%.
  • Its 3 year revenue growth rate is now at -100%.
Over the past 52 months, ZSAN's revenue has gone up $785,000.

The table below shows ZSAN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.785 -27.59 -29.925
2021-09-30 0.922 -28.041 -31.052
2021-06-30 0.67 -30.719 -31.071
2021-03-31 0.482 -30.734 -32.822
2020-12-31 0.224 -31.718 -33.369
2020-09-30 0 -32.903 -34.211

ZSAN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZSAN has a Quality Grade of F, ranking ahead of 0.35% of graded US stocks.
  • ZSAN's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
  • HGEN, ATRA, and ARMP are the stocks whose asset turnover ratios are most correlated with ZSAN.

The table below shows ZSAN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 0.201 -0.773
2021-03-31 0.007 0.309 -0.821
2020-12-31 0.004 0.237 -0.872
2020-09-30 0.000 NA -0.932
2020-06-30 0.000 NA -1.021
2020-03-31 0.000 NA -1.122

ZSAN Price Target

For more insight on analysts targets of ZSAN, see our ZSAN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.17 Average Broker Recommendation 1.33 (Strong Buy)

ZSAN Stock Price Chart Interactive Chart >

Price chart for ZSAN

ZSAN Price/Volume Stats

Current price $1.90 52-week high $37.45
Prev. close $1.73 52-week low $1.33
Day low $1.79 Volume 105,800
Day high $1.95 Avg. volume 395,711
50-day MA $4.49 Dividend yield N/A
200-day MA $16.07 Market Cap 9.31M

Zosano Pharma Corporation (ZSAN) Company Bio


Zosano Pharma Corporation provides biopharmaceutical products and services. The Company specializes in biopharmaceuticals, peptides, small water soluble molecules, monoclonal antibodies, and vaccines for the treatment of severe osteoporosis.


ZSAN Latest News Stream


Event/Time News Detail
Loading, please wait...

ZSAN Latest Social Stream


Loading social stream, please wait...

View Full ZSAN Social Stream

Latest ZSAN News From Around the Web

Below are the latest news stories about Zosano Pharma Corp that investors may wish to consider to help them evaluate ZSAN as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | February 22, 2022

FDA Rejects Zosano Pharma's Application For Zolmitriptan Microneedle System Again, Shares Plunge

The FDA has issued a response letter to Zosano Pharma Corp (NASDAQ: ZSAN) regarding its resubmission of the 505(b)(2) New Drug Application for M207 (zolmitriptan microneedle system). The response letter stated that the FDA did not consider the resubmitted M207 application a complete response to the deficiencies identified in the FDA’s October 2020 Complete Response Letter. The FDA will not begin a substantive review of the application until a complete response is received. The FDA’s response let

Yahoo | February 22, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | February 9, 2022

Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants

FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years f

Yahoo | February 9, 2022

Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants

FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actu

Yahoo | February 8, 2022

Read More 'ZSAN' Stories Here

ZSAN Price Returns

1-mo N/A
3-mo -75.87%
6-mo -92.08%
1-year -92.63%
3-year -98.20%
5-year -99.79%
YTD -88.45%
2021 -10.83%
2020 -65.32%
2019 -28.30%
2018 -79.62%
2017 -33.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0239 seconds.